FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

	ion 1(b).	ide. Gee		File	ed purs	uant to	Sectio	n 16(a) of the	e Secu	rities Exchan	ge Act c	f 1934			ours per	response.	0.5
	. , ,										ompany Act							
1. Name and Address of Reporting Person* HOLUBIAK MYRON Z						2. Issuer Name and Ticker or Trading Symbol BioScrip, Inc. [BIOS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 100 CLEARBROOK ROAD					3. Date of Earliest Transaction (Month/Day/Year) 12/14/2012									Officer (give to elow)			Other (specify below)	
(Street) ELMSFORD NY 10523 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - I	Non-Deriv	ative/	Sec	uritie	s Ad	cquire	ed, Di	sposed o	f, or E	Benefici	ally Ov	vned			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y					Execution Date,		·	3. Transaction Code (Instr. 8) 4. Securities Acq Disposed Of (D) (Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Followin Reported		F:	. Ownership orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price	Tr	ansaction(s) nstr. 3 and 4)			(111501. 4)
Common Stock, \$.0001 Par Value 12/14/20					012	12		S		10,000	D	\$10.82	32 ⁽¹⁾	20,000		D		
		Та	ıble II								oosed of, convertib				ed			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			and tt of ties ying tive ty (Instr. 3	8. Price Derivati Security (Instr. 5)	ve derivativ	ive ies cially ng ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	or Number of Shares					

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$10.79 to \$10.86, inclusive. The reporting person undertakes to provide BioScrip, Inc., any security holder of BioScrip, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

/s/ Myron Z. Holubiak 12/17/2012

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.